Pilot Trial for Treatment of Recurrent Glioblastoma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.
Eligibility criteria
Qualifiers
Study participant has provided informed consent prior to initiation of any study specific activities/procedures.
Adult participants, male and female, aged ≥18 who have a pathologically confirmed IDH-wild type glioblastoma, with first or second progression of the tumor, after initial treatment with radiation therapy and temozolomide.
Recurrence is amenable to resection.
Performance status: ECOG ≤2.
Disqualifiers
Patients with history of abnormal left ventricular ejection fraction (LVEF≤ 45%).
Pregnant, breast-feeding, unwilling/unable to comply with contraception requirements.
Patients unable to consent.
Hemoglobin <10,
Trial design
Treatments tested in this trial
- Afatinib
- Dasatinib
- Palbociclib
- Everolimus
- Olaparib
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
AHS Cancer Control Alberta
Lead sponsor
Tom Baker Cancer Centre
Collaborator
Source ClinicalTrials.gov